

**SPOTLIGHT**

# A calcium message for Niemann-Pick type C

Stephanie M. Cologna 

**Calcium is a ubiquitous secondary messenger that is critical for cellular function. In the highlighted article, Tiscione et al. (2019). *J. Cell. Biol.* <https://doi.org/10.1083/jcb.201903018>) describe a link between lysosomal cholesterol storage, calcium distribution alterations, and neuronal morphology in the neurodegenerative disorder Niemann-Pick type C.**

Calcium ions ( $\text{Ca}^{2+}$ ) are responsible for numerous cellular processes, and the role of  $\text{Ca}^{2+}$  as a secondary messenger is broad. Accordingly, defects in  $\text{Ca}^{2+}$  signaling have been implicated in several neurodegenerative disorders (1). Intracellular  $\text{Ca}^{2+}$  levels are regulated by activation of a variety of ion channels in the plasma membrane and the ER, which stores a substantial amount of  $\text{Ca}^{2+}$  (2, 3). In Tiscione et al., altered  $\text{Ca}^{2+}$  dynamics are shown in the fatal, lysosomal storage disease, Niemann-Pick type C (NPC; 4).

NPC is a fatal, genetic, lysosomal storage disorder that is biochemically characterized by lysosomal accumulation of unesterified cholesterol and glycosphingolipids (5). Mutations of the *NPC1* or *NPC2* genes, and therefore their respective proteins, result in impaired endo-lysosomal cholesterol trafficking, leading to cholesterol and glycosphingolipid accumulation in these compartments. As a result of this storage, a number of downstream alterations occur, including progressive cerebellar degeneration, and NPC has been referred to as childhood Alzheimer's disease. The mechanistic link between cholesterol storage and neurodegeneration, however, remains elusive and there is no FDA-approved therapy.

A  $\text{Ca}^{2+}$  defect in NPC was first proposed by Lloyd-Evans et al., with a specific focus on lysosomal  $\text{Ca}^{2+}$  alterations (6). Additional studies that implicated  $\text{Ca}^{2+}$  alterations were then expanded to include induced pluripotent stem cell-derived neurons (7) in regard to  $\text{Ca}^{2+}$  signaling and the WNT pathway, as well as connections to decreased  $\text{Ca}^{2+}$  flux and increased AMPA receptor expression (8). A proteomics study in brain tissue from

a NPC mouse model revealed differential expression of  $\text{Ca}^{2+}$  binding proteins as well as  $\text{Ca}^{2+}$ -regulated signaling pathways (9). Additionally, a linkage between  $\text{Ca}^{2+}$  and autophagy alterations in NPC was recently published (10), pointing to the timely nature of the current article.

In the study by Tiscione et al. (4), several key conclusions can be made. First, the loss of function of the *NPC1* cholesterol transporter results in increased flux of  $\text{Ca}^{2+}$  at the plasma membrane, yet decreased ER  $\text{Ca}^{2+}$  levels and overall increased resting cytosolic  $\text{Ca}^{2+}$  in NPC patient fibroblasts with different disease-causing mutations in the *NPC1* gene as well as in *NPC1* null cells and a pharmacologically induced NPC cell model. Second, defects at the plasma membrane contribute to  $\text{Ca}^{2+}$  alterations, namely, increased flux of  $\text{Ca}^{2+}$  across the plasma membrane, which is related to a channel-sensor system. Third, the authors then considered the  $\text{Ca}^{2+}$  ER stores as contributing factors, and, in fact, decreased ER luminal  $\text{Ca}^{2+}$  was observed in NPC, suggesting a "leaky"  $\text{Ca}^{2+}$  ER system. Additional contributions to  $\text{Ca}^{2+}$  defects in NPC were associated with the Presilin 1 protein.

Going back to the cholesterol defect in NPC, the study explores the role of the classical cholesterol biosynthesis and regulation pathways, namely, the membrane-bound sterol regulatory element binding protein (SREBP) pathway. From their data, the authors conclude that activation of SREBP contributes to the  $\text{Ca}^{2+}$  imbalance and signaling protein defects observed in NPC (4).

Ultimately, one may argue that understanding the mechanisms of defects to the central nervous system in NPC are the most critical aspects for making progress in the development of new therapies. Appropriately, Tiscione et al. (4) evaluate these observed deficits from their fibroblasts studies to cultured hippocampal neurons using the pharmacological NPC model and also in a point mutant mouse model of NPC. The authors find that neuronal  $\text{Ca}^{2+}$  is also decreased at the ER, whereas an increase in cytoplasmic  $\text{Ca}^{2+}$  is noted. Finally, the morphological changes observed in specific neuronal populations under cholesterol storage and, therefore,  $\text{Ca}^{2+}$  defects provide a glimpse into disease progression.

From the work by Tiscione et al., it is reasonable to consider how balancing  $\text{Ca}^{2+}$  levels may be an appropriate stance to consider in therapy development for NPC. While the primary defect in NPC certainly is lipid transport, the immediate link to altered  $\text{Ca}^{2+}$  levels and the crucial role of  $\text{Ca}^{2+}$  as a secondary messenger highlights the importance of these findings. It is also interesting to consider how changes in  $\text{Ca}^{2+}$  pools and signaling may occur during disease progression and if modulating these aspects could reduce the disease phenotype. This important study now provides additional insight into the molecular mechanisms leading to neurodegeneration in NPC (summarized in Fig. 1). As continued research efforts and clinical trials move forward, researchers should consider how modulating cholesterol storage may address deficits in  $\text{Ca}^{2+}$  pools and signaling or vice versa. This multifaceted approach will be

Department of Chemistry and Laboratory of Integrated Neuroscience, University of Illinois at Chicago, Chicago, IL.

Correspondence to Stephanie M. Cologna: [cologna@uic.edu](mailto:cologna@uic.edu).

© 2019 Cologna. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).




Figure 1. **Representative comparison of a control and a neuron with impaired or loss of NPC1 protein leading to NPC disease.** As a result, lysosomal cholesterol accumulates and  $\text{Ca}^{2+}$  flux across the plasma membrane and depleted  $\text{Ca}^{2+}$  stores in the ER increase. In neurons, this also shows decreased dendritic spines, relating the function to altered neuronal plasticity.

important, particularly in light of combination therapy methodologies.

### Acknowledgments

The author would like to thank Vince G. Amoroso and Fidel Serna-Perez for critical insight.

Support is acknowledged from the Department of Chemistry, College of Liberal

Arts and Sciences, University of Illinois at Chicago.

The author declares no competing financial interests.

- Okubo, Y., et al. 2018. *Antioxid. Redox Signal.* <https://doi.org/10.1089/ars.2018.7498>
- Ghosh, A., and M.E. Greenberg. 1995. *Science.* <https://doi.org/10.1126/science.7716515>
- Verkhatsky, A.J., and O.H. Petersen. 1998. *Cell Calcium.* [https://doi.org/10.1016/S0143-4160\(98\)90057-4](https://doi.org/10.1016/S0143-4160(98)90057-4)
- Tiscione, S.A., et al. 2019. *J. Cell Biol.* <https://doi.org/10.1083/jcb.201903018>
- Patterson, M.C., and S.U. Walkley. 2017. *Mol. Genet. Metab.* <https://doi.org/10.1016/j.ymgme.2016.11.008>
- Lloyd-Evans, E., et al. 2008. *Nat. Med.* <https://doi.org/10.1038/nm.1876>
- Efthymiou, A.G., et al. 2015. *Stem Cells Transl. Med.* <https://doi.org/10.5966/sctm.2014-0127>
- Rabenstein, M., et al. 2017. *Mol. Cell. Neurosci.* <https://doi.org/10.1016/j.mcn.2017.06.007>
- Pergande, M.R., et al. 2019. *Proteomics.* <https://doi.org/10.1002/pmic.201800432>
- Liu, E.A., and A.P. Lieberman. 2019. *Neurosci. Lett.* <https://doi.org/10.1016/j.neulet.2018.04.049>